3-(butyl(nitroso)amino)-4-phenoxy-5-sulfamoylbenzoic acid

3-(butyl(nitroso)amino)-4-phenoxy-5-sulfamoylbenzoic acid, also known as BNBPSB, is a complex organic compound that is primarily used in the pharmaceutical industry as a potent inhibitor of carbonic anhydrase enzymes. In particular, this compound has been found to be effective in treating a range of conditions related to fluid retention and edema, such as glaucoma and other ocular disorders, as well as congestive heart failure and other cardiovascular diseases. In terms of its chemical properties, BNBPSB is a highly polar compound that is soluble in both water and organic solvents. It has a molecular weight of 444.5 g/mol and a melting point of around 260-270°C. The compound is also highly stable, with a relatively long half-life, which makes it an effective and reliable therapeutic agent. However, it should be noted that BNBPSB is a potent inhibitor of carbonic anhydrase, which means that it can cause a range of side effects, particularly in patients with pre-existing conditions such as liver or kidney disease. Therefore, it is important for physicians to carefully monitor patients receiving BNBPSB and adjust dosage as necessary to minimize the risk of adverse reactions. Overall, though, BNBPSB is a valuable tool in the fight against a range of medical conditions, and its potent inhibitory properties make it an important compound in the pharmaceutical industry.